NFKB1 and carcinoma: The NF-kB inhibitory peptide reduced proliferation of talin deficient cells adherent to carcinoma matrix 4.22-fold and 2.08-fold (p = 0.033 and 0.006) respectively in the DMSO and 1 μM cisplatin treated cells (Figure 4D).